Fig. 3: AB928 enables efficient CAR T cell effector responses in vitro.
From: Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function
a RTCA of coculture with 5 × 104 murine anti-EpCAM CAR T cells and 2.5 × 104 Panc02-EpCAM tumour cells in the presence or absence of NECA (1 µM) and AB928 (1 µM). CAR T cells and treatments were added at the timepoint indicated by the arrow. b In all, 2.5 × 104 murine anti-EpCAM CAR T cells were cocultured with 2.5 × 104 Panc02-EpCAM tumour cells for 24 h in the presence or absence of NECA (100 nM) and AB928 (100 nM). GzmB concentrations in the coculture supernatant were determined by ELISA. c, e In all, 105 murine anti-EpCAM CAR T cells were activated with plate-bound recombinant EpCAM for c 18 h or e 48 h in the presence or absence of NECA (1 µM) and AB928 (1 µM). c Phenotypic characterisation of CAR T cells by flow cytometry. d Also, 105 murine anti-EpCAM CAR T cells were cocultured with 2.5 × 105 CT26-EpCAM tumour cells. Expression of inhibitory receptors on CD8+CAR+ T cells by flow cytometry. e CAR T cell proliferation was determined by flow cytometry with counting beads at the beginning and end of the experiment. Data were normalised to baseline proliferation of unstimulated cells. a, c Representative experiment of n = 3 independent experiments. Data represents mean of technical replicates. b, e Data are shown as mean ± SEM of b n = 7 or e n = 3 independent experiments with each dot representing the mean value of an individual experiment. d Representative experiment of n = 3 independent experiments. Data are shown as mean ± SEM of technical replicates. *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA.
